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Abstract: Chronic HBV + HDV infection is associated with greater risk of liver fibrosis, earlier hepatic
decompensation, and liver cirrhosis hepatocellular carcinoma compared to HBV mono-infection.
However, to-date no direct anti-HDV drugs are available in clinical practice. Here, we identified
conserved and variable regions in HBsAg and HDAg domains in HBV + HDV infection, a critical
finding for the design of innovative therapeutic agents. The extent of amino-acid variability was
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measured by Shannon-Entropy (Sn) in HBsAg genotype-D sequences from 31 HBV + HDV infected
and 62 HBV mono-infected patients (comparable for demographics and virological-parameters),
and in 47 HDAg genotype-1 sequences. Positions with Sn = 0 were defined as conserved.
The percentage of conserved HBsAg-positions was significantly higher in HBV + HDV infection than
HBV mono-infection (p = 0.001). Results were confirmed after stratification for HBeAg-status and
patients’ age. A Sn = 0 at specific positions in the C-terminus HBsAg were correlated with higher
HDV-RNA, suggesting that conservation of these positions can preserve HDV-fitness. Conversely,
HDAg was characterized by a lower percentage of conserved-residues than HBsAg (p < 0.001),
indicating higher functional plasticity. Furthermore, specific HDAg-mutations were significantly
correlated with higher HDV-RNA, suggesting a role in conferring HDV replicative-advantage.
Among HDAg-domains, only the virus-assembly signal exhibited a high genetic conservation (75% of
conserved-residues). In conclusion, HDV can constrain HBsAg genetic evolution to preserve its
fitness. The identification of conserved regions in HDAg poses the basis for designing innovative
targets against HDV-infection.
Keywords: HBsAg; HDV-RNA; HDAg
1. Introduction
Worldwide, an estimated 15 million individuals with chronic hepatitis B virus (HBV) infection are
infected with hepatitis D virus (HDV) [1]. Chronic HBV + HDV infection is associated with a greater
risk of liver fibrosis, earlier hepatic decompensation, and liver cirrhosis hepatocellular carcinoma
compared to HBV mono-infection [2,3]. Despite the severity of hepatitis D, no direct acting antiviral
drugs are so far available in clinical practice, and the diagnostic assays for HDV infection are not
fully standardized. Indeed, interferon alpha is the only anti-HDV drug approved for the treatment
of chronic hepatitis D, even if its efficacy is limited and side effects can be severe. Future therapeutic
options are under investigation targeting HDV entry, HBV surface antigen (HBsAg) secretion, and viral
assembly by inhibiting the farnesylation of HDV antigen (HDAg) [4].
So far, eight HDV genotypes have been identified. Except for genotype 1, which is represented
worldwide, all other genotypes are mostly found in specific geographical areas [5,6].
HDV is a peculiar virus since it requires HBsAg to infect the hepatocytes [7]. HDV genome is
composed by a 1.7 kb single-stranded circular RNA of negative polarity, whose replication requires
the involvement of the host RNA polymerase I and II [8,9]. The HDV genome contains only one
open reading frame encoding two isoforms of the delta antigen: the small and the large delta antigen
(S-HDAg composed by 195 amino acids and L-HDAg composed by 214 amino acids, respectively).
During the replication cycle, the expression of L-HDAg is mediated by host adenosine deaminase
(ADAR1) which modifies the stop codon at position 196 to a tryptophan codon in the antigenomic RNA.
S-HDAg is involved in the replication of viral genome, while L-HDAg is essential for the assembly of
new viral particles by interacting with HBsAg [10].
The S-HDAg contains different functional domains, such as three RNA-binding domains (RBD,
aa: 2–27; 97–107; 136–146), a coiled-coil sequence (CCS, aa: 31–67), and a nuclear localization sequence
(NLS, aa: 68–88) [11,12]. Beyond the aforementioned domains, L-HDAg contains the virus-assembly
signal (VAS, aa: 195–214), which plays a critical role in viral assembly [13].
The virus-assembly signal contains a carboxy-terminal CXXQ (C stands for cysteine, X for
any amino acid, and Q for glutamine) sequence for farnesylation [14–16]. The farnesyl group has
been proposed to anchor the L-HDAg to the endoplasmic reticulum membrane, where HBsAg is
synthesized [17]. The interaction between HBsAg and L-HDAg is crucial for HDV morphogenesis,
and thus for proper viral particle production. Although previous in vitro studies have investigated
mechanisms underlying the process of interaction between the HBsAg and L-HDAg [18,19], a paucity
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of information is available regarding the extent of genetic variability in HBsAg and HDAg in vivo in
patients with HBV + HDV infection. The identification of conserved regions in HDAg and HBsAg is
fundamental to identify essential domains crucial for HDV fitness, thus paving the way to identify
innovative pharmacological targets to prevent efficient HDV spread in the liver.
In this light, the goals of this study are: (i) to define and compare the degree of genetic variability in
HBsAg in the setting of HBV + HDV infection and HBV mono-infection; (ii) to define and characterize
variable and conserved regions in HDAg in patients with chronic HBV + HDV infection; (iii) to
correlate the extent of HBsAg and HDAg genetic variability with the levels of serum HDV-RNA
(reflecting HDV replicative potential in term of HDV particles production).
2. Materials and Methods
2.1. Study Population
This study included 78 consecutive patients with chronic HBV + HDV infection, followed in
different clinical centers (“Tor Vergata” University Hospital of Rome, Second University of Naples,
Hôpital Pellegrin Tripode of Bordeaux, Sandro Pertini Hospital of Rome). In order to provide more
readable data on the impact of HBsAg and HDAg genetic variability on serum HDV-RNA, all the 78
patients were naïve to interferon, the only currently available drug capable to affect HDV replication
and thus the levels of serum HDV-RNA.
Demographic, clinical, and virological data were collected for each patient and stored in
an ad hoc designed anonymous database. Serum HBV-DNA was quantified by Roche COBAS®
AmpliPrep/COBAS® TaqMan® HBV Test, v2.0 (Roche Molecular Diagnostics, Pleasanton, CA, USA),
while serum HDV-RNA was quantified a commercial HVD Real Time PCR assay (LifeRiver Diagnostics,
Shanghai ZJ Bio-Tech Co., Shanghai, China) Shanhai ZK Bio-tech.
Starting from 78 HBV + HDV infected patients, HBsAg genotype D and HDAg genotype 1
sequences were obtained for 31 and 47 patients, respectively. In order to compare HBsAg genetic
variability between HBV + HDV infection and HBV mono-infection, HBsAg sequences from 62 patients
with HBV genotype D monoinfection were also analyzed. Thirty-one HBV + HDV infected and 62
HBV mono-infected patients were comparable for sex, nationality, age, HBeAg status, HBV-DNA, and
anti-HBV drug received.
Ethic approval was deemed unnecessary because, under Italian law, biomedical research is
subjected to previous approval by ethics committees only in the hypothesis of clinical trials on
medicinal products for clinical use (art. 6 and art. 9, leg. decree 211/2003). The research was conducted
on viral DNA or RNA samples (used for clinical routine), and data previously anonymized, according
to the requirements set by Italian Data Protection Code (leg. decree 196/2003). Inform consent was
not necessary since the study was based on a retrospective analysis of anonymized viral sequences
obtained for clinical routine practice.
2.2. HBsAg and HDAg Sequencing
For each patient, HBV-DNA was extracted from plasma sample using a commercially
available kit (QIAmp DNA blood mini-kit, Qiagen Inc., Germantown, MD, USA), and then
HBsAg (aa:55–226) was amplified with Amplitaq-Gold polymerase using the following primer
pairs: HBV_F1-5′GGTCACCATATTCTTGGGAA and HBV_R1-5′GTGGGGGTTGCGTCAGCAAA.
Polymerase chain reaction (PCR) conditions were: one cycle at 93 ◦C for 12 min, 40 cycles
(94 ◦C 50 s, 57 ◦C 7 50 s, 72 ◦C 1 min and 30 s), and a final cycle at 72 ◦C for 10 min.
For samples with low serum HBV-DNA, a nested-PCR was performed, starting from the same
first amplicon, using the following primer pairs HBV_2D-5′GGTGGACTTCTCTCAATTTT and
HBV_7R-TGGCGAGAAAGTGAA. Nested-PCR conditions were: one cycle at 93 ◦C for 12 min,
30 cycles (94 ◦C 50 s, 55 ◦C 50 s, 72 ◦C 1 min and 20 s), and a final cycle at 72 ◦C for 10 min.
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For HDAg amplification and sequencing, HDV-RNA was extracted using a commercially available
kit (QIAmp RNA blood mini-kit, Qiagen Inc., USA), and then amplified with SuperScript III One-Step
RT-PCR with Taq Platinum High Fidelity (Invitrogen, Carlsbad, CA, USA) using the following primer
pairs: HDV_F1-5′CTTAGCCATCCGAGTGGACG and HDV_R1-5′GTCCAGCAGTCTCCTCTTTACA.
PCR conditions were: one cycle at 50 ◦C for 30 min, one cycle 94 ◦C for 2 min, 40 cycles
(94 ◦C 15 s, 61 ◦C 30 s, 68 ◦C 1 min and 30 s), and a final cycle at 68 ◦C for 10 min. For samples
with low serum HDV-RNA, a nested-PCR was performed starting from the same first amplicon.
The PCR-products were amplified with Amplitaq-Gold polymerase using the following primer pairs
HDV_F2-5′AGACGCAAACCTGYGAGTGG and HDV_R1 (mentioned before). Nested-PCR conditions
were: one cycle at 95 ◦C for 10 min, 30 cycles (95 ◦C 20 s, 61 ◦C 30 s, 72 ◦C 1 min), and a final cycle at
72 ◦C for 10 min.
PCR-products were purified and sequenced by using different overlapping sequence-specific
primers and a BigDye terminator v. 3.1 cycle sequencing kit (Applied-Biosystems, Foster City, CA,USA).
The sequences were analyzed using SeqScape-v.2.5 software (Thermo Fisher Scientific, Waltham,
MA, USA). The quality endpoint for each individual gene was ensured by a coverage of the HBsAg
and HDAg sequence by at least two segments. Sequences having a mixture of wild-type and mutant
residues at single positions were considered to have the mutant(s) at that position. The mixed base
identification was set at a percentage of 20%.
2.3. Phylogenetic Analysis
HBV and HDV genotypes were assessed by phylogenetic analysis using HBsAg and HDAg
sequences obtained by population-based sequencing. Nucleotide sequences of HBsAg and HDAg were
compared to reference sequences representing all known HBV and HDV genotypes retrieved from the
Genbank (HBV accession numbers: AB51639, FJ709464, AY090459, DQ899146, DQ899142, AB036920,
AF223965, GU563556, FN594748, JN664942, EU594434, GU456636, GQ477452, GQ205377, GQ922003,
FN594770, KF170740, FJ904442, AB486012, JN792893, GQ924617, GQ358147, GQ358137, GQ924640,
GQ358149, AB642091, FJ899779, GQ924626, FN545833, HE576989, JN182318, GQ331047, AB194951,
AY934764, FJ692613, FJ023659, FJ023664, AB644280, AB554025, AB644286, AB554019, AB644287,
AB540583, AP011106, HM011493, AB644284, EU410080, EU670263, GU721029, AP011108, GQ358158,
AB697490, DQ089801; HDV accession number: X04451, X60193, L22063, AF018077, AJ584848, AJ584847,
AJ584844, AJ584849) using MEGA 5.02 (https://www.megasoftware.net/). The phylogenetic analysis
was also performed to exclude possible contaminations and to define HBV and HDV genotypes.
The phylogenetic trees were generated with the Tamura–Nei model. The statistical robustness within
each phylogenetic tree was confirmed with a bootstrap-analysis using 1000 replicates.
2.4. Evolutionary Divergence
Shannon Entropy (Sn = −Σi(pi lnpi)/lnN) was calculated to measure the extent of amino acid
variability at each HBsAg and HDAg position, where pi was the relative frequency of each distinct
amino acid detected at a given position and n was the total number of sequences analyzed [20].
For HBsAg, Shannon-Entropy was calculated in the group of 31 HBV + HDV infected and 62 HBV
mono-infected patients, and stratifying HBV + HDV infected patients according to serum HDV-RNA
(>or <3.5 log serum HDV-RNA). In order to make result more readable, all the patients included in the
analysis were infected with HBV genotype D.
For HDAg, Shannon Entropy was calculated on 47 HBV + HDV coinfected patients, and stratifying
patients according to serum HDV-RNA (< or >4.5 log serum HDV-RNA).
The thresholds of 3.5 and 4.5 log IU/mL were chosen to stratify the 31 patients with HBsAg
sequences available and the 47 patients with HDAg sequences available in two numerically balanced
groups. Positions with SE = 0 were defined conserved.
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2.5. Statistical Analysis
Statistical data were analyzed using SPSS software (v19.0; SPSS Inc., Chicago, IL, USA). Data are
expressed as medians (interquartile range [IQR]) for continuous variables, and percentages for discrete
variables. The Chi-Squared Test based on a 2 × 2 contingency table was used for dichotomous data
while Mann–Whitney for continuous data. p < 0.05 was considered as statistically significant.
HBsAg three-dimensional structure prediction. The three-dimensional structure of HBsAg was
generated by using I_TASSER following a homology modeling approach with the original HBsAg
reference sequence as a modeling template [21,22]. UCSF Chimera software was used to color each
HBsAg residue according to its extent of genetic variability [23].
3. Results
3.1. Patients’ Characteristics
The main epidemiological and virological characteristics of the 78 patients with chronic HBV and
HDV infection are reported in Table 1.
Patients were prevalently males (65.4%) with a median (IQR) age of 51 (41–59) years.
Serum HBV-DNA was detected in 66 cases (84.6%) with a median (IQR) of 2.0 (1.3–3.1) log IU/mL.
Median (IQR) of ALT and AST were 68 (43–127) U/L and 66 (34–101) U/L, respectively. All patients
were HDV-RNA positive at qualitative testing. Seventeen patients (21.8%) had a serum HDV-RNA
below the lower limit of quantification (<2000 copies/mL). The remaining 61 patients (78.2%) had a
median (IQR) serum HDV-RNA of 4.7 (2.5–6.1) log IU/mL).
A negative correlation was observed between serum HBV-DNA and serum HDV-RNA
(Rho Spearman = −0.308; p value = 0.006).
Among 78 patients, 7 (9.3%) had a diagnosis of HCC, while 20 (28.2%) of cirrhosis (Table 1).
Among patients with therapy status available (n = 66), 50% (33/66) were exposed to at least one NUC.
Among the HBV + HDV infected patients with detectable serum HBV-DNA, HBsAg sequences
were obtained for 42 patients. Phylogenetic analysis revealed that most patients were infected with
HBV genotype D (31, 73.8%), followed by HBV genotype A (5, 11.9%), E (5, 11.9%), and B (1, 2.4%).
The analysis was focused on 31 patients infected with HBV genotype D, the majority of them were
infected with HBV subgenotype D3 (22, 71%), followed by subgenotype D1 (5, 16.1%), D4 (3, 9.7%)
and D2 (1, 3.2%). Among patients with serum HDV-RNA >2000 copies/mL, HDAg sequences were
obtained for 47 patients, all belonging to HDV genotype 1. No other HDV genotypes were detected.
Table 1. Characteristics of 78 patients with HBV + HDV infection.
Characteristics
Male, n (%) 51 (65.4%)
Italian, n (%) 42 (53.8%)
Median age (IQR), year 51 (41–59)
Median AST, IU/L (IQR) 66 (34–101)
Median ALT, IU/L (IQR) 68 (43–127)
Median serum HBV-DNA, log IU/mL (IQR) 2 (1.3–3.1)
Median serum HDV-RNA, log IU/mL (IQR) 4.7(2.5–6.1)
Current Treatment
NUCs, n( %) a 33 (50%)
Liver disease
Cirrhosis, n (%) 20 (28.2%)
Hepatocellular carcinoma, n (%) 7 (9.3%)
a Therapy status (drug-naïve/drug-treated) was available for 66 patients; Abbreviations: NUC, nucleos(t)ide reverse
transcriptase inhibitors; ALT, alanine-aminotransferase; AST aspartate aminotransferase.
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3.2. Characterization of HBsAg Genotype D Genetic Variability in HDV + HBV Infected and HBV
Mono-Infected Patients
The degree of HBsAg genetic variability in HBV + HDV infected patients was evaluated on
31 patients infected with HBV genotype D (the most common HBV genotype detected) and was
compared to that observed in a group of 62 patients with HBV genotype D mono-infection. HBV
mono-infected and HBV + HDV infected patients were comparable for sex, nationality, age, HBeAg
status, HBV-DNA, and anti-HBV drug received (Table 2).
Table 2. Characteristics of 31 HBV + HDV infected and 62 HBV mono-infected patients.
Characteristics HBV + HDV Infection HBV Mono-Infection p-Value
Male, n (%) 19 (61.3) 41 (66.1) 0.653
Italian, n (%) 18 (58.1) 41 (66.1) 0.498
Median age (IQR), year 51 (41–59) 49 (38–59) 0.554
Median HBV-DNA (IQR), log IU/mL 3.0 (1.8–3.4) 3.1 (2.5–3.9) 0.147
Median ALT (IQR), IU/L a 55 (28–94) 35 (25–52) 0.088
Median AST (IQR), IU/L a 46 (26–61) 26 (17–39) 0.004
Drug-Naïve, n (%) 17 (54.8) 37 (59.7) 0.626
a Median ALT and AST (IQR) was calculated on 47/62 HBV mono-infected patients and 29/31 HBV + HDV
coinfected patients with the datum available.
Firstly, Shannon Entropy was determined for each HBsAg amino acid position in both
HBV + HDV infected and HBV mono-infected patients.
Mean Shannon Entropy of HBsAg genotype D sequences from HBV + HDV infected patients was
significantly lower than that observed for HBsAg sequences from HBV mono-infected patients (mean
+ SD: 0.07+0.13 for HBV + HDV infection vs. 0.10 + 0.17 for HBV mono-infection, p < 0.01). In line with
this result, the number of conserved HBsAg positions (Sn = 0) was significantly higher in HBV + HDV
infected patients than in HBV mono-infected patients (119/172 [69.2%] vs. 90/172 [52.3%], p = 0.001).
Comparing the two groups of patients, the percentage of conserved positions was different in each
HBsAg domain: 88.6% ([39/44] vs. 70.5% [31/44] (p = 0.062) for the N-terminus, 71.8% [51/71] vs.
53.5% [38/71] (p = 0.037) for the major hydrophilic region (MHR), and 50.9% [29/57] vs. 35.1% [20/57]
(p = 0.130) for HBsAg C-terminus (Figures 1 and 2).
0
20
40
60
80
100
HBsAg (aa:55-226) N-terminus
(aa:55-98)
MHR (aa:99-169) C-terminus
(aa:170-226)
%
 o
f c
on
se
rv
ed
 p
os
iti
on
s
HBV mono-infected patients HBV+HDV infected patients
** *
Fig.1
Figure 1. The histogram reports the percentage of conserved HBsAg positions in 31 HBV + HDV
coinfected patients (grey bars) and 62 HBV mono-infected patients (black bars). Conserved positions
are those with Shannon Entropy = 0. Statistically significant differences were assessed by Chi Square
Test. ** p = 0.001; * p = 0.037.
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Fig.2
Figure 2. Three-dimensional structure of HBV genotype D HBsAg. HBsAg structure was built by
using I-TASSER [24], and colored by using UCSF Chimera [23]. In patients with chronic HBV + HDV
infection (A) and HBV mono-infection (B), residues were colored according to the percentage of
mutations detected: 0% Blue, 0.1–5% Yellow, 6–20% Orange and >20% Red.
Furthermore, specific positions in N-terminus (n = 11), MHR (n = 19) and C-terminus (n = 12)
were conserved only in HBV + HDV infected patients (Figure 3 and Figure S1).
The percentage of conserved residues throughout the entire HBsAg genotype D sequences
remained higher in HBV + HDV infected patients than in HBV mono-infected patients when the
analysis was focused on HBeAg-negative patients (77.9% vs. 59.3%). Focusing on the major hydrophilic
region, the percentage of conserved residues was 81.7% in HBV + HDV HBeAg-negative infected
patients and 59.2% in HBV HBeAg-negative mono-infected patients (p = 0.005).
Furthermore, the percentage of conserved residues showed a stable trend in patients aged
<45 years, 45–55 years and >55 years in either HBV + HDV infected and HBV-mono-infected patients
(Table 3), excluding the impact of patients’ age on the extent of HBsAg genetic variability.
Table 3. Percentage (n) of HBsAg conserved residues by stratifying patients according to age a.
HBV + HDV Infected Patients c HBV Mono-Infected Patients d
Amino Acids
Positions <45 Years 45–55 Years >55 Years p Value
b <45 Years 45–55 years >55 Years p Value b
55–98 aa 97.7 (43) 97.7 (43) 93.2 (41) 0.221 88.6 (39) 86.4 (38) 84.1 (37) 0.117
99–169 aa 85.9 (61) 83.1 (59) 88.7 (63) 0.602 78.9 (56) 83.1 (59) 70.4 (50) 0.602
170–226 aa 73.7 (42) 70.2 (40) 84.2 (48) 0.602 52.6 (30) 70.2 (40) 49.1 (28) 0.602
total 55–226 aa 84.9 (146) 82.6 (142) 88.4 (152) 0.602 72.7 (125) 79.7 (137) 66.9 (115) 0.602
a The % was calculated on the total number of residues within each HBsAg domain; b p values were calculated by
Chi Squared test for trend; c HBV + HDV coinfected patients were stratified according to age: <45 years (n = 10),
45–55 years (n = 13), and > 55 years (n = 8); d HBV mono-infected patients were stratified according to age: <45 years
(n = 26), 45–55 years (n = 16), and > 55 years (n = 20).
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Figure 3. The histogram reports the Shannon Entropy (Sn) value at HBsAg positions in HBV
mono-infected patients (black bars) and HBV + HDV infected patients (grey bars). Conserved positions
(Sn = 0) in both HBV + HDV infected and HBV mono-infected patients were not reported in the
histogram. Shannon Entropy was calculated according to the following formula Sn = −Σi(pi lnpi)/lnN)
where pi was the relative frequency of each distinct amino acid detected at a given position and n was
the total number of sequences analyzed.
Focusing on patients aged <45 years or >55 years, the percentage of conserved residues was
higher in HBV + HDV infected than in HBV mono-infected patients (<45 years: 84.9% vs. 72.7%,
p value = 0.006 for <45 years and 88.4% vs. 66.9%, p value < 0.001 for >55 years).
The HBsAg cytosolic loop II (CYL-II) encompassing the amino acid 194–201 is known to be
important for the interaction of HBsAg C-terminus with the virus-signal of L-HDAg [25]. In line with
this finding, the Shannon Entropy of this region was significantly lower in HBV + HDV infection
than in HBV mono-infection (mean+sd: 0.04 + 0.07 in HBV + HDV infection vs. 0.20 + 0.19 in HBV
mono-infection, p = 0.042). Furthermore, 6 out of 8 CYL-II residues were conserved (Sn = 0) in
HBV + HDV infected patients while only 2 in HBV mono-infected patients (p = 0.046) (Figure 3 and
Figure S1).
Conversely, the cytosolic loop I (CYL-I) encompassing the amino acid 56–80 is known to bind
both HBV core particles and HDAg [26,27], and was conserved in both HBV + HDV infection and HBV
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mono-infection (21/25 conserved residues in HBV + HDV infection vs. 19/25 in HBV mono-infection)
(Figure 3 and Figure S1).
3.3. Correlations between Specific HBsAg Mutations and the Level of Serum HDV-RNA
A further step in this study was to investigate whether the extent of genetic variability at
specific HBsAg positions can affect the levels of serum HDV-RNA (reflecting HDV replicative
potential and thus the burden of HDV particles produced). To achieve this goal, Shannon Entropy
was calculated at each HBsAg position in the group of 14 patients with lower serum
HDV-RNA (serum HDV-RNA < 3.5 log IU/mL), and in the group of 17 patients with higher serum
(HDV-RNA > 3.5 log IU/mL). The HBsAg positions 204 and 206 were found conserved (Sn = 0) in the
group of patients with higher serum HDV-RNA, while they were mutated only in the group of patients
with lower serum HDV-RNA (% of mutated residues: 0 [0%] vs. 6 [42.9%], p = 0.007 for position 204;
0 [0%] vs. 3 [21.4%], p = 0.045 for position 206) (Figure 4). In addition, analyzing HBsAg position 207,
some specific mutations were detected only in the group of patients with lower HDV-RNA and were
never detected in patients with higher serum HDV-RNA (S207R/T/I: 0 vs. 6 [42.9%], p = 0.007).
These findings suggest that an enrichment of mutations at specific positions in HBsAg genotype D
C-terminus may be detrimental for the interaction between HBsAg and the virus-assembly signal of
L-HDAg, thus affecting HDV replicative potential.
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Figure 4. Association of mutated positions in HBsAg with levels of HDV-RNA. The histogram reports
the percentage of patients with at least one mutation at HBsAg position 204 (A) and 206 (B) calculated
in the group of patients with HDV-RNA <3.5 log IU/mL (n = 14) and with HDV-RNA >3.5 log IU/mL
(n = 17). The prevalence of each mutation, detected at HBsAg positions 204 and 206, is reported
in each bar. Statistically significant differences were assessed by Chi Squared Test based on 2 × 2
contingency table.
3.4. Characterization of HDV Genotype 1 HDAg Genetic Variability
The next step of this study was to define the extent of HDAg genotype 1 genetic variability.
Firstly, Shannon Entropy was calculated in the group 47 HDV genotype-1 infected patients. A lower
percentage of conserved residues was observed in HDAg than HBsAg (49.5% for HDAg vs. 69.2% for
HBsAg, p < 0.001), highlighting a lower degree of genetic conservation in HDAg than in HBsAg.
By stratifying patients HDV genotype-1 infected patients according to age (<45 years, 45–55 years
and >55 years), there were no differences in terms of HDAg conserved positions (65.9%, 65.4% and
69.2%, respectively).
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Furthermore, analyzing each HDAg domain, the lowest percentage of conserved residues was
found in the RNA binding domain I and III, as well as in the coil–coil signal (23.1% [6/26], 27.3% [3/11],
and 27.3% [6/22], respectively), followed by the RNA binding domain II (54.5%, 6/11), and the nuclear
localization signal (52.3%, 11/21) (Figure 5A,B). A higher degree of conservation was found in the
virus-assembly signal (aa: 195–214) than in the other HDAg domains (75% [15/20] vs. 35.2% [32/91],
p < 0.002) (Figure 5A,B). Similarly, the mean Shannon Entropy was significantly lower in the nuclear
export signal and virus-assembly signal than in the other HDV domains (mean + SD: 0.164 + 0.324 vs.
0.24 + 0.33, p = 0.003).
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Figure 5. (A) Degree of HDAg conservation. The figure reports the number of conserved positions
in each HDAg functional domains: RNA-binding domain (RBD), coiled–coil sequence (CCS),
nuclear localization sequence (NLS), nuclear export signal (NES) and virus assembly signal (VAS).
HDAg domains are defined according to Pascarella et al., 2010 [28]. (B) The histogram reports the
Shannon Entropy (Sn) value at HDAg positions in 47 HDV genotype-1 infected patients. Conserved
positions (Sn = 0) were not reported in the histogram. Shannon Entropy was calculated according to
the following formula Sn = −Σi(pi lnpi)/lnN) where pi was the relative frequency of each distinct
amino acid detected at a given position and n was the total number of sequences analyzed.
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It is known that the phosphorylation of serine at HDAg positions 2 and 177 of S-HDAg increases
HDV replication. In our cohort, the position 2 was conserved in 95.7% (45/47) patients, while S177
was completely conserved (Figure S2).
Then, Shannon Entropy was calculated stratifying 47 HDV genotype-1 infected patients according
to serum HDV-RNA: 18 patients with serum HDV-RNA <4.5 log IU/mL, and 29 with serum
HDV-RNA >4.5 log IU/mL. A lower percentage of conserved residues was observed in patients
with higher serum HDV-RNA than in patients with lower serum HDV-RNA (55.6% [119/214]
vs. 65.9% [141/214], p = 0.037) (Figure 6A). Notably, the HDAg mutations S6R, A22S and L90S
occurred with significantly higher frequency in patients with higher serum HDV-RNA than in patients
with lower serum HDV-RNA (S6R: 24.1% [7/29] vs. 0% [0/18], p = 0.034; A22S: 72.4% [21/29] vs.
33.3% [6/18], p = 0.015; L90S: 31% [9/29] vs. 0% [0/18], p = 0.008) (Figure 6B). Furthermore, the
presence of at least one of these mutations was correlated with a significantly higher median (IQR)
serum HDV-RNA (5.7 [5.1–6.3] log IU/mL in presence vs. 4.4 [3.8–5.6] log IU/mL in absence of S6R,
A22S and L90S, p = 0.003). S6R and A22S are localized in RNA binding domain I, while L90S is close
to nuclear localization signal (domains important for HDV life cycle). Overall findings suggest that
these mutations may confer a replicative advantage to HDV genotype 1.
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Figure 6. Association of mutated positions in HDAg with levels of HDV-RNA. (A) The histogram
reports the percentage of conserved HDAg positions in patients with serum HDV-RNA <5 log IU/mL
(n = 18) and in patients with serum HDV-RNA >5 log IU/mL (n = 29). (B) The histogram reports
the percentage of patients with HDAg mutations S6R, A22S, and L90S calculated in patients with
serum HDV-RNA <5 log IU/mL (n = 18) and in patients with serum HDV-RNA >5 log IU/mL (n = 29).
Statistically significant difference was assessed by Chi Squared Test based on a 2 × 2 contingency table.
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4. Discussion
This is one of the first studies showing a higher degree of genotype D HBsAg conservation
in the setting of chronic HBV + HDV infection than in HBV mono-infection, highlighting that the
accumulation of mutations in HBsAg in vivo can be detrimental for HDV replicative potential.
Conversely, genotype 1 HDAg was characterized by a substantially higher degree of genetic
variability in most domains with the exception of the nuclear export signal and the virus-assembly
domain. The identification of conserved regions in HBsAg and HDAg functional domains is crucial
for the rational design of innovative anti-HDV drugs and for improving the accuracy of diagnostic
assays for HDV infection.
HBsAg (particularly specific regions in HBsAg C-terminus) plays a pivotal role in HDV
morphogenesis by interacting with the virus assembly signal of L-HDAg, the most conserved HDAg
domain (75% of conserved residues). This supports that a higher degree of HBsAg conservation can be
necessary to preserve the interaction between these two proteins, thus allowing a proper assembly
and release of HDV particles. Thus, it is conceivable that HDV can exert a selective pressure on HBV
favoring the production of wild-type HBsAg.
To further corroborate this concept, we found an inverse correlation between the percentage of
conserved residues and levels of serum HDV-RNA.
It can be argued that the higher degree of genetic variability in HBV mono-infection may be related
the collection of patients with a longer infection history. In order to address this issue, we focused the
attention on HBeAg-negative patients, and we found that the percentage of conserved HBsAg residues
remained higher in HBV + HDV infected patients than in HBV mono-infected patients (77.9% vs.
59.3%). Furthermore, in either HBV + HDV infected and HBV-mono-infected patients, the percentage
of conserved residues showed a stable trend in patients aged <45 years, 45–55 years and >55 years.
Focusing the attention on patients aged <45 years or >55 years, the percentage of conserved residues
was again higher in HBV + HDV infected than in HBV mono-infected patients (<45 years: 84,9% vs.
72.7%, p-value 0.006 for <45 years and 88.4% vs. 66.9%, p-value <0.001 for >55 years).
Notably, we identified specific positions in genotype D HBsAg C-terminus (204 and 206)
completely conserved in HBV + HDV infected patients with higher serum HDV-RNA (a biomarker
to directly measure HDV replicative potential in vivo). Conversely, these positions were found
mutated only in patients with lower serum HDV-RNA, suggesting that the presence of mutations
at these positions can be detrimental for HDV replication potential. In line with this hypothesis, the
positions 204 and 206 are localized in the 4th HBsAg transmembrane domain (critical to allow a proper
positioning of HBsAg in the membrane of endoplasmic reticulum) [29], and in close proximity of
the CYL-II (aa: 194–201) known to bind L-HDAg [25]. Previous in vitro studies have shown that
mutations or deletions in HBsAg C-terminus can impair the interaction between HBsAg C-terminus
and L-HDAg, thus hampering the proper envelopment of HDV ribonucleoprotein and in turn viral
particles production [25]. Further studies are necessary to verify if an impairment in HBV envelopment
caused by mutations in HBsAg can lead to an intracellular accumulation of HDAg thus worsening
disease progression. It is also conceivable that HDV strains can further undergo a process of viral
adaptation in order to preserve or increase their viral fitness. Further longitudinal studies are necessary
to address HDV genetic evolution during the course of chronic infection.
Previous studies have shown that the Trp (W) at HBsAg position 196 is required for efficient
assembly of stable HDV particles, for its central localization in binding interface with L-HDAg [30–32].
These studies showed that the mutations W196F, W196S, and W196L can abrogate HDV release [31].
Notably, due to the overlapping between the genes coding for the RT and HBsAg, W196L corresponds
to the drug resistance mutation M204I. Interestingly, we detected W196L only in HBV mono-infected
(8%) and never in HBV + HDV infected patients. Conversely, previous in vitro studies showed no
detrimental effect on HDV release in presence of I195M (corresponding to the drug resistance mutation
M204V). In line with this result, the prevalence of I195M was comparable between HBV + HDV
infected and HBV mono-infected patients. These results support that HDV coinfection can constrain
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HBsAg evolution and modulate the emergence of drug-resistance profiles. This can have important
implications for those countries in which anti-HBV drugs with lower genetic barrier are still used since
M204V can also favor the emergence of cross-resistance to entecavir.
It is known that the level of serum HBV-DNA is usually lower than in HBV + HDV infected
than in HBV mono-infected patients [33], and this might provide an explanation for the lower rate of
HBsAg variability observed in the setting HBV + HDV infection. However, longitudinal studies have
shown considerable fluctuating activity of one or both viruses with alternating predominance of HDV
or HBV, highlighting a highly dynamic interplay between these two viruses [33,34].
Beyond HBV genotype D, we also detected patients infected with HBV genotype A (5, 11.9%),
E (5, 11.9%), and B (1, 2.4%). Further studies are warranted in order to evaluate if the genetic
background of different HBV and HDV genotypes can affect the interplay between HBV and HDV
replicative potential in vivo.
In our study, we have analysed HBsAg sequences from plasma plasma. Indeed, there is a
consensus on the fact that viral species circulating in patient’s plasma reflect viral species that have
been originated in liver and have spread in the bloodstream. In line with this concept, we have
analysed an independent set of 16 HBV chronically infected patients with concomitant plasma and
liver biopsies available, and we calculated for each pair of plasma/liver sequence the genetic distance
(number of different nucleotides/1000 nucleotides). We found that the genetic distance between HBsAg
sequence from plasma and liver ranges from 0/1000 nucleotides to 8/1000 nucleotides (median [IQR]:
2.8 (0.3–2.8)). This supports a superimposable predominant species in plasma and liver compartments.
A different scenario was observed for HDV genotype 1 HDAg showing a significantly higher
degree of variability than HBsAg.
The high degree of HDAg genotype 1 genetic variability (particularly in the small isoform) is
in line with the definition of S-HDAg protein as an intrinsically disordered protein lacking of an
ordered conformation. In particular, it has been proposed that the plasticity of S-HDAg may favor the
interaction with a large number of cellular partners, modulating host metabolic functions, contributing
to enhance viral replication and promote more acute and adverse forms of the liver disease [35]. This is
in line with our results, showing the correlation between a higher degree of genetic variability and
higher serum HDV-RNA.
Mechanisms underlying HDV genetic variability have not been clarified yet. HDV forces host
RNA polymerase II to act as a RNA-dependent RNA polymerase to replicate viral genome. It is
conceivable that the RNA polymerase II may acquire an error prone nature when RNA is used as
template. As recently described, RNA polymerase II may contribute not only to the generation of
point mutations but can also promote events of recombination, further enhancing HDAg genetic
variability [36,37]. As postulated by recent studies, other mechanisms including ADAR1 and Apobec
enzymes may represent a source of HDV genetic variability [38]. Further studies are necessary to
investigate this intriguing hypothesis.
The high degree of HDAg genotype 1 genetic variability can have important clinical implications.
Firstly, it can hamper HDAg recognition by the currently available serological and molecular assays for
HDV diagnosis and staging [39], thus highlighting the need of a joint effort to optimize the accuracy
of diagnostic assays for HDV infection. Secondly, the high degree of genetic variability might also
explain the very low rate of response to interferon-based treatment. Indeed, interferon-based treatment
is known to stimulate immune-response against the virus that can be hampered by the accumulation
of mutations in HDAg epitopes. Longitudinal studies are necessary to investigate this point.
Among the different HDAg genotype 1 domains, the virus-assembly signal was characterized
by a higher degree of genetic conservation. These regions may represent target for the design of
innovative anti-HDV drugs. In line with this concept, a recent proof of concept study has shown that
the prenylation inhibitor lonafarnib, acting on the virus-assembly signal can reduce serum HDV-RNA
in patients with HBV + HDV infection [40–42].
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The need of innovative anti-HDV drugs is also critical in the light of a recent study showing HDV
persistence (presumably in the form of latent infection) in patients with a limited HBV replication
and after liver transplantation [43]. Even more intriguingly, another study has shown that chronic
HDV infection can persist in the absence of HBV replication (or when HBV replication is profoundly
suppressed) if functional HBsAg is supplied from integrated HBV-DNA [44].
Furthermore, the identification of conserved HBsAg or HDAg regions can pose the basis for
the design of innovative therapeutic strategies such as gene-therapy or RNA interference whose
efficacy can be compromised by the accumulation of mutations in HBV or HDV genome. In particular,
homing endonucleases, such as zinc-finger endonucleases (ZFNs), transcription activator-like effector
nucleases (TALENs), and RNA-guided clustered regulatory interspaced short palindromic repeats
associated with the Cas endonuclease family (CRISPR/Cas) have been shown to cleave selected
sequences in cccDNA, thus favoring the disruption and elimination of cccDNA [45,46]. Conversely,
RNA interference (by inhibiting the translation of HBV proteins) can remarkably decrease the burden
of viral antigens (including HBsAg) circulating in patients’ sera (Flisiak et al., Expert Opin Biol Ther.
2018) [47]. These approaches have been so far investigating in HBV, further studies are necessary to
investigate their role in counteracting HDV replication.
5. Conclusions
In conclusion, genotype D HBsAg genetic conservation was significantly higher in the setting of
chronic HBV + HDV infection than in HBV mono-infection, suggesting HDV role in constraining HBV
genetic evolution in order to preserve HDV fitness. Conversely, genotype 1 HDAg is characterized
by a higher degree of genetic variability with the exception of the nuclear export signal and the
virus-assembly signal. The identification of conserved regions in HBsAg and HDAg is crucial for the
rational design of innovative anti-HDV drugs and for improving the accuracy of diagnostic assays of
HDV infection.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/10/7/
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